August 28, 2014 1:12 PM ET

Pharmaceuticals

Company Overview of InnoPharma, LLC

Company Overview

InnoPharma, LLC develops niche generic and specialty pharmaceutical/bio-pharmaceutical products. The company develops sterile injectable and ophthalmic pharmaceutical products. It also works with manufacturing and clinical research organizations worldwide for commercialization of its developed products. InnoPharma, LLC was founded in 2005 and is based in Piscataway, New Jersey.

10 Knightsbridge Road

Piscataway, NJ 08854

United States

Founded in 2005

Phone:

732-885-2939

Fax:

732-885-1248

Key Executives for InnoPharma, LLC

Co-Founder and Chief Operating Officer
Chief Financial Officer
Age: 50
Vice President of Business Development & Alliance Management
Vice President of Project Management
Compensation as of Fiscal Year 2014.

InnoPharma, LLC Key Developments

Sandoz Canada to Make, Use, Sell, Market and Distribute InnoPharma's Olanzapine Injection in Canada

InnoPharma Inc. announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa(R) injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania. As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.

InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM

InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Navneet Puri, Founder, Chief Executive Officer, President and Director.

InnoPharma Inc. Completes $20 Million Term Loan Facility

InnoPharma, Inc. announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the company's ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction.

Similar Private Companies By Industry

Company Name Region
Balance Therapeutics Inc. United States
Glyconix Corp. United States
Neuraltus Pharmaceuticals, Inc. United States
Oncotarget Inc. United States
Noble Molecules, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 16, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InnoPharma, LLC, please visit www.innopharmallc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.